Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Patents
  • Published:

Evergreening: a common practice to protect new drugs

Nature Biotechnology volume 29, pages 876–878 (2011)Cite this article

Subjects

The common strategy of evergreening using patents and other exclusivity periods likely contributes to the total incentives that justify a pharmaceutical company's investment in a new drug.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Characteristics of patent exclusivities associated with NDAs.
Figure 2: Characteristics of FDA-approval exclusivities associated with NDAs.

References

  1. Kate, K.T. & Laird, S.A. The Commercial Use of Biodiversity: Access to Genetic Resources and Benefit-Sharing (Earthscan, London, 1999).

  2. DiMasi, J.A. & Grabowski, H.G. The cost of biopharmaceutical R&D: Is biotech different? Manage. Decis. Econ. 28, 469–479 (2007).

    Article  Google Scholar 

  3. 35 USC §§ 102–103.

  4. 21 USC § 355(b)(1)(G).

  5. See 35 USC §§ 102–103.

  6. United States Patent and Trademark Office. US Dept. of Commerce, Manual of Patent Examining Procedure § 800 (8th ed., 8th rev. 2010) (hereinafter MPEP).

  7. MPEP § 2701.

  8. 21 USC § 355(j)(5)(F)(ii).

  9. 21 USC § 355(j)(5)(F)(iii).

  10. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations: Exclusivity Codes (FDA, 2011). http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm

  11. 21 CFR § 355(c)(3)(E)(iv).

  12. 21 USC § 360(aa)-(cc).

  13. 21 USC § 355a.

  14. Id.

  15. Scherer, F.R. The link between gross profitability and pharmaceutical R&D spending. Health Aff. 20, 216–220 (2001).

    Article  CAS  Google Scholar 

  16. Food and Drug Administration. Drug approval reports. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Reports.ReportsMenu

  17. Department of Health and Human Services, Letter to Katherine Gaudry. (Freedom of Information Act Request No. 2010–6543), Jan. 17, 2011.

Download references

Acknowledgements

The author would like to thank B. Roin and P. Hutt for their review of and suggestions for this manuscript.

Author information

Authors and Affiliations

  1. Kate S. Gaudry is a recent graduate from Harvard Law School.,

    Kate S Gaudry

Authors
  1. Kate S Gaudry
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kate S Gaudry.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaudry, K. Evergreening: a common practice to protect new drugs. Nat Biotechnol 29, 876–878 (2011). https://doi.org/10.1038/nbt.1993

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.1993

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research